CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences , Beijing 100049, China.
College of Materials Science and Optoelectronic Technology, University of Chinese Academy of Sciences , Beijing 100049, China.
ACS Appl Mater Interfaces. 2018 Jan 31;10(4):4271-4284. doi: 10.1021/acsami.7b17506. Epub 2018 Jan 22.
Chemotherapy resistance remains a major hurdle for cancer therapy in clinic because of the poor cellular uptake and insufficient intracellular release of drugs. Herein, an intelligent, multifunctional MoS nanotheranostic (MoS-PEI-HA) ingeniously decorated with biodegradable hyaluronic acid (HA) assisted by polyethyleneimine (PEI) is reported to combat drug-resistant breast cancer (MCF-7-ADR) after loading with the chemotherapy drug doxorubicin (DOX). HA can not only target CD44-overexpressing MCF-7-ADR but also be degraded by hyaluronidase (HAase) that is concentrated in the tumor microenvironment, thus accelerating DOX release. Furthermore, MoS with strong near-infrared (NIR) photothermal conversion ability can also promote the release of DOX in the acidic tumor environment at a mild 808 nm laser irradiation, achieving a superior antitumor activity based on the programmed response to HAase and NIR laser actuator. Most importantly, HA targeting combined with mild NIR laser stimuli, rather than using hyperthermia, can potently downregulate the expression of drug-resistance-related P-glycoprotein (P-gp), resulting in greatly enhanced intracellular drug accumulation, thus achieving drug resistance reversal. After labeled with Cu by a simple chelation strategy, MoS was employed for real-time positron emission tomography (PET) imaging of MCF-7-ADR tumor in vivo. This multifunctional nanoplatform paves a new avenue for PET imaging-guided spatial-temporal-controlled accurate therapy of drug-resistant cancer.
化疗耐药性仍然是癌症治疗中的一个主要障碍,因为药物的细胞摄取能力差和细胞内释放不足。在此,报告了一种智能的多功能 MoS 纳米治疗剂(MoS-PEI-HA),巧妙地用可生物降解的透明质酸(HA)修饰,由聚乙烯亚胺(PEI)辅助,负载化疗药物阿霉素(DOX)后用于治疗耐药乳腺癌(MCF-7-ADR)。HA 不仅可以靶向 CD44 过表达的 MCF-7-ADR,还可以被透明质酸酶(HAase)降解,透明质酸酶集中在肿瘤微环境中,从而加速 DOX 的释放。此外,具有强近红外(NIR)光热转换能力的 MoS 也可以在温和的 808nm 激光照射下促进酸性肿瘤环境中 DOX 的释放,基于对 HAase 和 NIR 激光致动器的程序化响应,实现卓越的抗肿瘤活性。最重要的是,HA 靶向结合温和的 NIR 激光刺激,而不是使用高热,可有效地下调耐药相关 P-糖蛋白(P-gp)的表达,导致细胞内药物积累大大增加,从而实现耐药逆转。通过简单的螯合策略用 Cu 标记后,MoS 用于 MCF-7-ADR 肿瘤的体内实时正电子发射断层扫描(PET)成像。这种多功能纳米平台为 PET 成像引导的耐药性癌症时空可控精确治疗开辟了新途径。